Security Notice: Please be aware of impersonation attempts using our company name
Legitimate communications from Ascent Research will only come from official @ascentresearch.com email addresses.
Quick Order Cart

Cat. No. ARG1753

CYTH1 Knockout Raji Polyclonal Cells

  • Product Type:

    Polyclonal Cell Population

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Bone

  • Disease:

    Burkitt lymphoma

The CYTH1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from Raji B lymphoblasts, with disruption of the CYTH1 gene encoding cytohesin-1. Cytohesin-1 acts as a GEF for ARF1 and ARF6, recruited by PIP3 and interacting with integrin beta-2 (CD18) to regulate LFA-1 activation, actin remodeling, and lymphocyte adhesion. These cells are designed for B cell adhesion and migration studies, integrin activation assays (e.g., CD18/CD11a conformation monitoring), ARF-GTP immunoprecipitation, and research on Burkitt lymphoma, leukocyte adhesion deficiency, and PI3K/AKT pathway mechanisms. The polyclonal format provides a heterogeneous loss-of-function model for dissecting CYTH1-dependent signaling in B cell biology and lymphomagenesis.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    Raji

    Cell Type

    B cell line

    Sex of Donor

    Male

    Age

    11 years

    Derived From Site

    In situ; Maxilla

    Gene Name

    CYTH1

    Gene Identifier

    NCBI Gene ID 9267

    Morphology

    Lymphoblast-like

    Growth Mode

    Suspension

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Growth medium

    RPMI 1640

    Supplement(s)

    10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The CYTH1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte cell line, featuring disruption of the CYTH1 gene. This polyclonal pool provides a loss-of-function model for studying CYTH1-dependent processes without the selection of single-cell clones, maintaining genetic diversity representative of the edited population. The knockout enables investigation of CYTH1??s role in guanine nucleotide exchange factor activity and integrin-mediated cellular functions.

The parental Raji cell line is a human B lymphoblast line originally established from a male patient with Burkitt lymphoma. Raji cells are Epstein?CBarr virus (EBV)-positive and grow in suspension, serving as a well-characterized model for EBV latency, B cell receptor (BCR) signaling, and oncogenic mechanisms in hematological malignancies. Their lymphoblastoid phenotype recapitulates key features of B cell biology, making them suitable for studying adhesion, migration, and immune synapse formation.

CYTH1 encodes cytohesin-1, a guanine nucleotide exchange factor (GEF) that activates ARF small GTPases, principally ARF1 and ARF6, by catalyzing GDP/GTP exchange. Its pleckstrin homology (PH) domain mediates membrane recruitment through binding to phosphatidylinositol (3,4,5)-trisphosphate (PIP3), a product of PI3K signaling. Direct interaction of CYTH1 with the cytoplasmic tail of integrin beta-2 (ITGB2/CD18) promotes conformational activation of LFA-1 (CD11a/CD18), leading to enhanced ligand binding and outside-in signaling. Downstream, activated ARF6 and RAC1 coordinate actin cytoskeleton remodeling via PIP5K, driving processes such as cell adhesion, spreading, and transendothelial migration. Signaling inputs from BCR, chemokine receptors (CXCR4), and CD19 converge on PI3K/PIP3 to regulate CYTH1 localization and activity.

In the Raji B cell context, CYTH1 disruption is particularly relevant for dissecting integrin-dependent adhesion and migration pathways that underpin lymphocyte trafficking and immune surveillance. Since Raji cells endogenously express LFA-1 and exhibit robust adhesion to ICAM-1, ablation of CYTH1 provides a system to interrogate the GEF?Cintegrin coupling required for firm adhesion under flow and transendothelial migration. Furthermore, because EBV latency and BCR signaling drive PI3K/PIP3 production, the CYTH1 knockout model allows investigation of how pathogenic signaling in Burkitt lymphoma co-opts cytohesin-mediated integrin activation to promote lymphoma cell dissemination and microenvironment interactions.

Typical applications of these polyclonal knockout cells include flow cytometry-based monitoring of integrin activation using conformation-specific antibodies against CD18/CD11a, static and flow adhesion assays on ICAM-1 substrates, transwell migration assays toward chemokines such as SDF-1??, and immunoprecipitation to detect ARF-GTP loading. The cells are also suited for high-content imaging of F-actin dynamics, western blotting for PI3K/AKT pathway effectors, and RNA-seq to identify transcriptomic changes upon CYTH1 loss. For further details on this product, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)